For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 1,809,209 | 1,432,138.25* | 1,661,646 | 2,447,286 |
| General and administrative expenses | 1,522,005 | 1,182,127* | 1,827,197 | 1,503,497 |
| Operating loss | -3,331,214 | -2,614,265.25* | -3,488,843 | -3,950,783 |
| Other income | - | 5,000* | - | - |
| Unrealized gain on digital assets at fair value | - | 73,795* | - | - |
| Unrealized loss on digital assets at fair value | 59,824 | - | - | - |
| Interest and dividend income, net | 13,859 | 27,372.75* | - | - |
| Other income, net | - | - | 52,270 | 16,865 |
| Net operating loss before income tax benefit | -3,377,179 | -2,508,097.5 | - | - |
| Net loss | -3,377,179 | -2,508,097.5 | -3,436,573 | -3,933,918 |
| Basic EPS | -1.29 | -1.916 | -0.07 | -0.25 |
| Diluted EPS | -1.29 | -1.916 | -0.07 | -0.25 |
| Basic Average Shares | 2,623,143 | 1,309,271* | 47,525,522 | 15,569,312 |
| Diluted Average Shares | 2,623,143 | 1,309,271* | 47,525,522 | 15,569,312 |
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)